Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Concern about a new virus in China is providing a big catalyst for this biotech.

Why Novavax Stock (NVAX)  Is Skyrocketing Today

Aethlon Medical

BioCryst Pharmaceuticals

Inovio Pharmaceuticals

Shares of several vaccine makers were on the rise Tuesday following reports of a spreading coronavirus outbreak in Asia.

4 Vaccine Stocks Making Big Moves Amid Coronavirus Outbreak

Shares of Novavax Inc. NVAX, +20.08% rallied 60% in premarket trading on Tuesday on heavy volume.

Novavax shares jump 60% in premarket trading

BioMarin Pharmaceutical

CRISPR Therapeutics

These stocks could thump the broader markets this year.

3 Top Biotech Picks for 2020

The FDA bestows a Fast Track Designation on Novavax's (NVAX) influenza vaccine candidate NanoFlu for adults aged 65 years and older. Shares rally.

Novavax Rises on Fast Track Designation to Influenza Vaccine

Investors hope NanoFlu gets the stock back on track in 2020.

Novavax Wins Fast-Track Designation for Flu Vaccine

Novavax Inc. (NASDAQ: NVAX) shares jumped on Wednesday after the U.S. Food and Drug Administration (FDA) granted a Fast Track Designation for NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate, adjuvanted with Matrix-M, in adults 65 years of age and older.

Does FDA Decision Mean a Bright Future for This Flu Vaccine?

Novavax Inc. shares NVAX, +1.01% soared 20% in premarket trade Wednesday, after the late-stage biotech said it has received fast track designation from the U.S.

Novavax shares soar 20% premarket after company wins FDA fast-track designation for flu vaccine

GAITHERSBURG, Md., Jan.  15, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for NanoFlu™, its recombinant quadrivalent seasonal influenza vaccine candidate, adjuvanted with Matrix-M™, in adults 65 years of age and older.

Novavax Granted Fast Track Designation for NanoFlu in Older Adults

Novavax: Investors Prepare For A Decisive 2020

Aerie Pharmaceuticals

Akebia Therapeutics

Cytokinetics

Telesis Bio Inc

For investors seeking out the ultimate high-risk, high-reward stocks, look no further than the biotech industry.

5 “Strong Buy” Biotech Stocks With More Than 80% Upside

These two pharma micro-caps are approaching climactic phase 3 trials.

Better Buy: Novavax vs. Inovio Pharmaceuticals

Novavax's (NVAX) CEO Stan Erck on Q3 2019 Results - Earnings Call Transcript

This tiny biotech has a long history of failure, but it also has a flu vaccine that is likely to be approved by the FDA.

Could Novavax Be a Millionaire-Maker Stock? (NVAX)

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Novavax (NVAX) Report Negative Q3 Earnings? What You Should Know

Novavax (NVAX) starts a pivotal late-stage study on its pipeline candidate NanoFlu influenza vaccine in senior patients. Shares up.

Novavax Begins Phase III Study on Influenza Vaccine Candidate

GAITHERSBURG, Md., Oct.  15, 2019  (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the initiation of a pivotal Phase 3 clinical trial for NanoFlu™, its recombinant quadrivalent seasonal influenza vaccine candidate, in adults aged 65 and over. The trial, for which the first participants have been enrolled, will evaluate the immunogenicity and safety of NanoFlu with its proprietary Matrix-M™ adjuvant, compared to a U.S.-licensed quadrivalent influenza vaccine.

Novavax Initiates Pivotal Phase 3 Clinical Trial of NanoFlu Influenza Vaccine in Older Adults

Beazer Homes USA

NVIDIA

Odonate Therapeutics

Studies have shown that a majority of successful stocks see acceleration in earnings before an uptick in the stock price.

4 of the Best Stocks With Solid Earnings Acceleration

GAITHERSBURG, Md., Sept.  19, 2019  (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C. Erck, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2019 Healthcare Conference.

Novavax to Present at the Ladenburg Thalmann 2019 Healthcare Conference

GAITHERSBURG, Md., Sept.  06, 2019  (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C. Erck, President and Chief Executive Officer, will present at the H. C. Wainwright 21st Annual Global Investment Conference.

Novavax to Present at the H.C. Wainwright 21st Annual Global Investment Conference

CNH Industrial N.V. (NYSE: CNHI / MI: CNHI), today will announce its new five-year 2020 – 2024 business plan ‘Transform 2 Win’ at its Capital Markets Day event in New York, U.S.A., presenting a detailed strategy to transform the Company’s structure and performance to empower its five operating segments achieve their full potential.

Novavax: Rising From The Depths

Cooper Companies

Maxar Technologies

Veeco Instruments

Studies have shown that a majority of stocks had seen acceleration in earnings before a rally in stock price.

4 Stocks That Boast Superb Earnings Acceleration

Novavax's RSV vaccine may not be dead after all.

Why Novavax Stock (NVAX) Is Soaring Today

Novavax, Inc. (NVAX) CEO Stan Erck on Q2 2019 Results - Earnings Call Transcript

Novavax (NVAX) seeks to use accelerated approval pathway for its influenza vaccine candidate, NanoFlu, in the United States.

News for Novavax Stock (NVAX)